Clinical Study
Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
Table 3
Treatment-emergent adverse events for the two groups.
| Treatment toxicities | Number of patients (%) | Group 1 () | Group 2 () | Total () |
| Grades 1-2 | | | | Neutropenia or leukopenia | 22 (44.9%) | 13 (65%) | 35 (50.7%) | Anemia | 15 (30.6%) | 8 (40%) | 23 (33.3%) | Thrombocytopenia | 11 (22.4%) | 7 (35%) | 18 (26.1%) | Infection | 0 | 1 (5%) | 1 (1.4%) | Nausea or emesis | 25 (51.0%) | 9 (45%) | 34 (49.3%) | Fatigue | 31 (63.3%) | 13 (65%) | 44 (63.8%) | Constipation | 19 (38.8%) | 10 (50%) | 29 (42.2%) | Others | 5 (10.2%) | 2 (10%) | 7 (10.1%) | Grades 3-4 | | | | Hematologic toxicities | 8 (16.3%) | 7 (35%) | 15 (21.7%) | Nonhematological toxicities | 0 | 1 (5%) | 1 (1.4%) |
|
|